Among many ICIs identified, anti-PD1/PD-L1 and anti-CTLA-4 are currently approved for clinical application, and combination treatment of anti-PD1 and anti-CTLA-4 could have synergistic effect in some kinds of cancer (160–163). Here, CTLA4 is linked to cancer.